Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models

Anti-Cancer Drugs

Volumn 10, Issue 10, 1999, Pages 911-920

  Bandak, Suzan ^a   Goren, Dorit ^a   Horowitz, Aviva ^a   Tzemach, Dina ^a   Gabizon, Alberto ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cisplatin; Liposomes; Pharmacokinetics; SPI 077

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; LIPOSOME; MACROGOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER SURVIVAL; CIRCULATION TIME; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG RELEASE; DRUG TISSUE LEVEL; ENCAPSULATION; FEMALE; KIDNEY; LIVER; LUNG CARCINOMA; LYMPHOMA; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SURVIVAL TIME; TUMOR MODEL; TUMOR VOLUME;

EID: 0033400567     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199911000-00007     Document Type: Article

References (27)

1. Carter SK. Cisplatin - past, present and future. In: Hacker MP, Douple EB, Krakoff IH, eds. Platinum coordination complexes in cancer chemotherapy. Boston, MA: Martinus Nijhoff 1984: 359-76.
2. Durant JR. Cisplatin: a clinical overview. In: Prestayko AW, Crooke ST, Carter SK, eds. Cisplatin, current status and new developments. New York: Academic Press 1980: 317-21.
3. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumors. Drugs 1997; 54: 15-21.
4. Han I, Ling YH, Al-Baker S, Khokhar A, Perez-Soler R. Cellular pharmacology of liposomal cis-bis-neodecanoatotrans-R,R-1,2-diamino-cyclohexaneplatinum (II) in A-2780/S and A-2780/PDD cells. Cancer Res 1993; 53: 4913-9.
5. Mori A, Wu SP, Han I, Khokhar AR, Perez-Soler R, Huang L. In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) formulated in long-circulating liposomes. Cancer Chemother Pharmacol 1996; 37: 435-44.
6. Papahadjopoulos D, Gabizon A. Liposome targeting to tumor cells in vivo. In: Gregoriadis G, et al., eds. Targeting of Drugs New York: Plenum Press 1990: 95-101.
7. Gabizon A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992; 52: 891-6.
8. Huang SK, Mayhew E, Gilani S, et al. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992; 52: 6774-81.
9. Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochem Biophys Acta 1991; 1070: 187-92.
10. Newman SN, Colbern GT, Working P, Engbers C, Amantea M. Comparative pharmaco-kinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating liposomes, pegylated liposomes (SPI-077) in tumor bearing mice. Cancer Chemother Pharmacol 1999; 43: 1-7.
11. Vaage J, Donovan D, Wippf E, et al. Therapy of a xenographted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int J Cancer 1999; 80: 134-7.
12. Working P, Newman MS, Sullivan T, et al. Comparative intravenous toxicity of cisplatin encapsulated in long-circulating pegylated liposomes in cynomolgus monkeys. Toxicol Sci 1998; 46: 155-65.
13. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol-coated liposomes. Cancer Res 1994; 54: 987-92.
14. Hong WK, Shapshay SM, Bhutani R, et al. Induction chemotherapy in advanced squamous head and neck carcinoma with high-dose cis-platinum and bleomycin infusion. Cancer 1979; 44: 19-25.
15. Horowitz A, Barenholz Y, Gabizon A. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim Biophys Acta 1992; 1109: 203-9.
16. Souhami RL, Patel HM, Ryman BE. The effect of reticuloendothelial blockade on the blood clearance and tissue distribution of liposomes. Biochim Biophys Acta 1981; 18: 354-71.
17. Greene RF, Chatterji DC, Hiranaka PK, Gallelli JF. Stability of cisplatin in aqueous solution. Am J Hosp Pharmac 1979; 36: 38-43.
18. Hincal AA, Long DF, Repta AJ. Cisplatin stability in aqueous parenteral vehicles. J Paventer Drug Ass 1979; 33: 107-16.
19. Allen TM, Newman MS, Woodle MC, Mayhew E, Uster PS. Pharmacokinetics and antitumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 1995; 62: 199-204.
20. Colbern G, Dykes D, Enbers C, et al. Encapsulation of topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmaco-kinetics and antitumor activity in HT29 colon tumor xenografts. Clin Cancer Res 1998; 4: 3077-82.
21. Storm G, Kate MT, Working P, Bakker-Woudenberg I. Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system. Clin Cancer Res 1998; 3: 111-5.
22. Gabizon A, Goren D, Horowitz T, Tzemach T, Lossos A, Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing mice. Adv Drug Del Rev 1997; 24: 337-44.
23. Reed E, Dabholkar M, Chabner B. Platinum analogues. In: Chabner B, Longo L, eds. Cancer chemotherapy and biotherapy. Philadelphia, PA: Lippincott-Raven 1996: 357-78.
24. Heudi O, Mercier JS, Calliex A, Allain P. Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin. Biopharm Drug Disp 1999; 20: 107-16.
25. Saudek V, Pivcoca H, Noskova D, Drobnik J. The reaction of Pt-antitumor drugs with selected nucleophiles. Preparation and characterization of coordination compunds of Pt (II) and L-histidine. J Inorg Biochem 1985; 23: 55-72.
26. Boni C, Savoldi L, Bisagni G, et al. Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomized trial of the Italian oncology group for clinical research. Eur J Cancer 1998; 34: 1974-6.
27. Ikeda K, Terashima M, Kawamura YH, et al. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol 1998; 28: 168-75.